Cat. No. |
Product Name |
Information |
PC-21782 |
HSL119
HUNK inhibitor
|
HSL119 (HSL 119) is a potent and selective hormonally upregulated neu-associated kinase (HUNK) inhibitor, completely inhibits HUNK kinase activity at 1 uM in biochemical assays. |
PC-21761 |
BI-4732
EGFR inhibitor
|
BI-4732 is a potent, highly BBB penetrant, fourth-generation EGFR inhibitor against EGFR activating mutations, including C797S. |
PC-20669 |
Zongertinib
HER2 inhibitor
|
Zongertinib (BI 1810631, BI-1810631) is a potent, selective HER2 inhibitor, binds to the TKD of HER2 while sparing wild-type EGFR. |
PC-20044 |
Mifanertinib
EGFR inhibitor
|
Mifanertinib (Mefatinib free base) is a potent selective EGFR and HER2 kinase inhibitor with potential for for treatment of cancer. |
PC-49519 |
HCD3514
EGFR C797S inhibitor
|
HCD3514 is a novel potent, selective, fourth-generation EGFR inhibitor targeting C797S triple mutation, strongly inhibits EGFRL858R/T790M/C797S and EGFR19del/T790M/C797S mutations with IC50 of 1.0 and 2.0 nM, respectively. |
PC-49365 |
EGFR inhibitor 57
EGFR L858R inhibitor
|
EGFR inhibitor 57 is a novel potent, selective, allosteric fourth-generation EGFR L858R inhibitor, overcomes EGFRC797S-mediated resistance in NSCLC harboring the activating EGFRL858R mutation. |
PC-49235 |
DSF-102
EGFR ECD inhibitor
|
DSF-102 (DSF102) is a small molecule EGFR inhibitor that interacts with the extracellular domain (ECD) of EGFR, inhibits the interaction with the EGF instead of blocking the intracellular kinase activity, shows inhibition of EGFR dimerization with IC50 of 13.2 uM. |
PC-49227 |
BI-1622
HER2 inhibitor
|
BI-1622 (BI 1622) is a potent, selective, covalent and orally active HER2 inhibitor with IC50 of 7 nM, potently inhibits HER2 exon 20 mutants while sparing WT EGFR. |
PC-49226 |
BI-4142
HER2 inhibitor
|
BI-4142 (BI 4142) is a potent, selective, covalent and orally active HER2 inhibitor with IC50 of 5 nM, potently inhibits HER2 exon 20 mutants while sparing WT EGFR. |
PC-47006 |
OBX02-011
EGFR TKI
|
OBX02-011 is a potent, reversible, fourth-generation EGFR tyrosine kinase inhibitor (TKI) that overcomes the EGFR C797S mutation, inhibits triple mutants Del19/T790M/C797S and L858R/T790M/C797S with IC50 of 0.134 and 2.09 nM, respectively. |
PC-38641 |
LDC0496
EGFR inhibitor
|
LDC0496 is a potent, covalent, wild type-sparing inhibitor of EGFR exon20 insertion mutations, exhibits intense inhibitory potency toward EGFR and Her2 exon20 insertion mutations as well as selectivity over wild type EGFR and within the kinome. |
PC-38640 |
LDC8201
EGFR inhibitor
|
LDC8201 is a potent, covalent, wild type-sparing inhibitor of EGFR exon20 insertion mutations, exhibits intense inhibitory potency toward EGFR and Her2 exon20 insertion mutations as well as selectivity over wild type EGFR and within the kinome. |